Bio-Techne Q3 revenue $316.2M (+6% organic), adj EPS $0.56, declares $0.08 dividend and $500M buyback

BIO-TECHNE Corp

2025-Q3 EPS reported $0.57 vs consensus $0.43 ▲ beat (+33.0%)

Q3 organic revenue +6% to $316.2M; GAAP EPS $0.14 vs $0.31 YoY; adjusted EPS $0.56 vs $0.48 YoY.
Protein Sciences segment organic growth 7% (reported 6%) on improved pharma demand and commercial execution.
Adjusted operating margin improved to 34.9% from 33.0% YoY; reported margin 12.2% (incl. charges).
Declared quarterly dividend $0.08/share, payable May 30, 2025 to holders of record May 19, 2025.
Board approved new $500M share repurchase program, effective May 8, 2025, replacing prior program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.